Important note: Information in this article was accurate in Summer 2001. The state of the art may have changed since the publication date.
 |
(RITA!)HIV Treatment Alerts - July 2001
SMART
They call it SMART and it launches on Monday, October 15, 2001. SMART stands for Strategies for the Management of Anti-Retroviral Therapy, and it will be the largest, most ambitious clinical trial in the history of the HIV/AIDS epidemic. The study will involve 6000 patients and last for as long as 8 years.
Driven by the widespread recognition that anti-HIV drugs are toxic, the study's planners are hoping to learn whether delayed, discontinuous treatment for HIV is just as effective as the present strategy of immediate, uninterrupted treatment. The study will also gather information on the long-term side effects of HIV treatment and its effect on quality of life. Additionally, the study will seek to learn whether interruptions in treatment are associated with an increase in unsafe sex.
The study is open to anyone with HIV, male or female, who is at least 13 years old. To volunteer, you must have a T cell count of at least 350 and you must be willing to start, stop, or change anti-HIV drug therapy, depending on the study group to which you are assigned. For the first year of the study, you will have to see the doctor once every 2 months. After that, you will see the doctor 3 times a year. For safety, you cannot volunteer for the study while you are pregnant, but you can volunteer after you have had your baby.
In Houston, this study will be available at 3 sites: Thomas Street Clinic, the Veteran's Administration Medical Center, and Montrose Clinic. The principal investigator (head doctor) for the study is Roberto Arduino, MD, an associate professor of medicine at the University of Texas–Houston Medical School.
For more information, call Hilda Cuervo at 713.500.6731.
Compliance Study Launches at Thomas Street Clinic
Even though HIV disease has become a "chronic" disease, it is unlike many other chronic disease states (such as hypertension and diabetes) because compliance in HIV care has unparalleled social and public health influences. Many factors interfere with compliance, including continued substance abuse, competing subsistence needs (like housing, clothing, etc.), difficulties in accessing care, and poor support from peer groups, employers, and family members. All of these factors lead to failure to come for scheduled clinic appointments and to refill prescriptions on time. Thus, overall compliance is poor, which will likely limit options for future therapy, worsen disease outcome, and possibly even increase the potential for transmitting drug-resistant virus.
A new study is being launched at Houston's Thomas Street Clinic to look at interventions that might improve compliance among women in traditionally underserved populations. A grant for $243,000 was generously awarded by Bristol Myers Squibb to fund the project. Dr. Fehmida Visnegarwala, Director of Education at Thomas Street Clinic and an assistant professor of medicine at Baylor College of Medicine, will oversee the study.
The study proposes to establish a quality improvement program for 100 women followed for an average of 18 months in an attempt to increase compliance with clinic visits and anti-HIV medications. This will be accomplished by providing patients with sufficient understanding of
For those participants identified with active drug use, effective drug-rehabilitation services will be provided. The study will test if an intensive early-intervention program will give patients the desire and skills needed to use the health care delivery system to their best advantage. Women receiving care at Thomas Street Clinic are eligible to enroll in this study. For more information, contact Mary Caprio (713.873.4185).
Dr. Fehmida Visnegarwala (center) displays her award check for a new HIV/AIDS care compliance intervention study for women in underserved communities. Thomas Gegeny, Editor at The Center for AIDS, is on the left. Steven Nettles, of Bristol-Myers Squibb (the study sponsor), is on the right.
20010710
RI010707
Copyright © 2001 - Research Initiative Treatment Action (RITA!). Reproduced with permission. RITA! is published by The Center for AIDS. Contact Thomas Gegeny, MS, ELS, Editor, RITA! for permission to reproduce RITA!. tom@centerforaids.org. http://www.centerforaids.org
ÆGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1985, 2001. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content.